|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Pharmos Corporation (Nasdaq: PARS), a developer of therapeutics to treat disorders of the central and peripheral nervous systems and systemic disorders involving inflammation and autoimmune dysfunctions |
|---|---|
| Transferring Party | Vela Pharmaceutical, Inc., a venture-capital backed, privately owned company specializing in the development of medicines related to diseases of the nervous system including disorders of the "brain-gut axis." |
| Sector | Biopharmaceuticals |
| Date | March 17, 2006 |
| Analysis Creates a combined drug development company focused primarily on diseases of the nervous system and autoimmune disorders. Deal value about $29.7m -- $5.0m cash; balance Pharmos stock, plus additional stock if clinical milestones are hit. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |